Biogen, the company behind Spinraza, has announced that they will engage with NHS England and NICE with a view to initiate Managed Access, an interim scheme that will make Spinraza available to all those with SMA while NICE performs formal appraisal.
The National Institute for Health and Care Excellence (NICE) announced that it will appraise Spinraza as a treatment for all those with spinal muscular atrophy
On 2 January 2018 all mailboxes of TreatSMA were suspended by Google without warning. As a result, the TreatSMA team lost access to all emails, address books and shared documents which until then were hosted on Google’s G Suite service.
The Scottish Medicines Consortium (SMC) will shortly start assessing nusinersen (Spinraza™) for use in NHS Scotland for the treatment of SMA Types 1, 2 and 3.
Last Friday NHS England sent a disappointing response to our letter on access criteria to Spinraza under Expanded Access Programme.
Efforts continue on bringing about changes to the NHS commissioning policy on nusinersen. Last night almost 40 clinicians and the four UK SMA groups sent another letter to NHS England. The letter underlined our position that nusinersen treatment under the Expanded Access Programme should be provided to all those who have type 1 SMA.
I wish you knew the turmoil my heart is in with every single waking beat. I wish you felt the lump in my throat caused by the overwhelming fear of defeat. I wish you saw what I see when I…